Video Interview: Probiodrug Pursues Modified Abeta Approach To Tackle Alzheimer's
This article was originally published in Scrip
Probiodrug AG CEO Dr. Konrad Glund tells Mike Ward, global director of content for Informa's pharma insights portfolio, about his company's differentiated approach to targeting Alzheimer's disease. Probiodrug is targeting glutaminyl cyclase, an enzyme that is key to production of pyroglutamate modified Abeta (pGlu-Abeta), a toxic variation of Abeta that has a crucial role in the formation of Abeta plaques.
Register for our free email digests: